Registry update — unassessed
Nicotinamide Riboside Supplementation for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
RCTRoutine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Oct 2, 2026 · Discovered: Oct 2, 2026 · Assessed: — · Research update
What it does not prove
- The abstract does not specify the magnitude of the blood pressure or arterial stiffness changes in the main trial, making it unclear whether effects are clinically meaningful. The study enrolled only adults with mildly elevated blood pressure, so findings may not generalize to those with higher baseline pressure. Long-term effects beyond 3 months are unknown.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 3 months
- Population
- Middle-aged and older men and women with systolic blood pressure between 120 and 139 mmHg at baseline
- Primary outcome
- Systolic blood pressure and arterial stiffness
- Effect size
- —
- Significance
- Not reported
- Journal
- Douglas Seals
- Published
- Oct 2, 2026
Sources
Primary source
- Douglas Seals ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
As a next translational step, we will conduct a randomized, placebo-controlled, double-blind clinical trial to further assess the safety and efficacy of oral nicotinamide riboside (3 months vs placebo) for decreasing SBP and arterial stiffness in middle-aged and older men and women with SBP between 120 and 139 mmHg at baseline.
We recently completed the first pilot study of nicotinamide riboside supplementation in healthy middle-aged and older adults and demonstrated that 6 weeks of supplementation decreased systolic blood pressure (SBP) by 8 mmHg in individuals with baseline SBP of 120-139 mmHg (elevated SBP/stage 1 hypertension) compared with placebo, and lowered arterial stiffness
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.